ADRB3
ENSG00000188778
Target class
GPCR
Chromosome
8
Approved drugs
18
Clinical candidates (approved and in development)
23
- Approved drugs
- 18
- Clinical candidates (approved and in development)
- 23
- Chemical probe available
- Yes
- Target name
- ADRB3
- Gene name
- Adrenoceptor beta 3
- Gene symbol
- ADRB3
- Protein name
- Beta-3 adrenergic receptor (Beta-3 adrenoreceptor) (Beta-3 adrenoceptor)
- Gene biotype
- Protein coding
- Gene family
- Adrenoceptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 7
- Protein localisation evidence grade
- Uncertain
- Highest tissue expression
- 24.87
- Tissue specificity (Gini)
- 0.891
- Tissue specificity (tau)
- 0.969
- KEGG gene identifiers
- hsa:155
- Protein interaction confidence
- 0.828556
- Protein interaction partners
- 18
- R-HSA-390696
- R-HSA-418555
- End position
- 37966599
- Start position
- 37962990
- Chromosome
- 8
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein .
- Tissue specificity (tau)
- 0.969077
- Expression inequality (Gini)
- 0.890737
Expression in transcripts per million
- Ovary
- 24.87
- Bladder
- 10.47
- Esophagus - Muscularis
- 7.86
- Fallopian Tube
- 7.77
- Esophagus - Gastroesophageal Junction
- 4.82
Expression in transcripts per million
- Ovary24.87
- Bladder10.47
- Esophagus - Muscularis7.86
- Fallopian Tube7.77
- Esophagus - Gastroesophageal Junction4.82
- Colon - Sigmoid3.25
- Colon - Transverse1.12
- Uterus0.99
- Cervix - Endocervix0.82
- Prostate0.58
- Stomach0.52
- Small Intestine - Terminal Ileum0.36
- Cervix - Ectocervix0.29
- Vagina0.23
- Adipose - Visceral (Omentum)0.19
- Brain - Cortex0.18
- Esophagus - Mucosa0.17
- Brain - Frontal Cortex (BA9)0.12
- Lung0.12
- Kidney - Medulla0.11
- Testis0.1
- Brain - Anterior cingulate cortex (BA24)0.09
- Brain - Amygdala0.09
- Breast - Mammary Tissue0.08
- Adipose - Subcutaneous0.06
And 29 more, listed on the interactive page.
- GO:0005975
- GO:0006091
- GO:0006112
- GO:0006898
- GO:0007187
- GO:0007188
- GO:0007193
- GO:0043410
- GO:0045744
- GO:0045986
- GO:0055118
- GO:0070374
- GO:0071880
- GO:0071881
- GO:0005886
- GO:0043235
- GO:0003925
- GO:0004939
- GO:0005515
- GO:0015052
- GO:0042803
- GO:0051380
receptor binding
Studies
- biochemical: NVS_GPCR_hAdrb3, is one of one assay component(s) measured or calculated from the NVS_GPCR_hAdrb3 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.
Biological samples
- cell-free
Evidence source
Related records
Trials (3,006)
- : Vascular Function in Health and Disease
- ''Efficacy of Propranolol in the Treatment of Infantile Hemangioma"
- "Pecos" B-adrenergic and PPAR-G Stimulation Upregulates Lipid Metabolism in Human Subcutaneous Fat
- "The Effect Of Subcutaneous Epinephrine Dosage On Blood Loss In Surgical Incision"
- "The Evaluation of Stimulant Withdrawal"
- 10 Vs.15 mcg Norepinephrine Bolus in Severe Maternal Hypotension During Cesarean Delivery
- 12-week Efficacy of Indacaterol
- 12-week Open-label Evaluation of Efficacy and Safety of Indacaterol
- 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation
- 24 Hour Ambulatory Cardiac Oxygen Consumption
- 24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension
- 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy
- 24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration.
- 24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients
- 24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination
- 24-Hour Intraocular Pressure Control With Bimatoprost/Timolol Versus Latanoprost as First Choice
- 24-hour Intraocular Pressure Control With Travoprost/Timolol Fixed Combination Versus Travoprost
- 24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations
- 24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease
- 26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Drugs (72)
- Abediterol
- Acebutolol
- Albuterol
- Alprenolol
- Amibegron Beta-3 adrenergic receptor agonist
- Amibegron hydrochloride Beta-3 adrenergic receptor agonist
- Atenolol
- Betaxolol
- Bisoprolol
- Bucindolol
- Bunolol
- Bupranolol
- Carazolol
- Carteolol Adrenergic receptor beta antagonist
- Carteolol hydrochloride Adrenergic receptor beta antagonist
- Carvedilol Adrenergic receptor beta antagonist
- Carvedilol phosphate Adrenergic receptor beta antagonist
- Cimaterol
- Clenbuterol
- Denopamine